Antimicrobial properties of MX-2401, an expanded-spectrum lipopeptide active in the presence of lung surfactant

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 8, 2011, Pages 3720-3728

  Dugourd, Dominique ^a,c   Yang, Haiyan ^a,b   Elliott, Melissa ^b   Siu, Raymond ^a   Clement, Jacob J ^a   Straus, Suzana K ^b   Hancock, Robert E W ^b   Rubinchik, Evelina ^a  

^a BioWest Therapeutics Inc   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BD Diagnostics Infectious Disease   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFOMYCIN; CALCIUM ION; CEFOTAXIME; DAPTOMYCIN; FUSIDIC ACID; LUNG SURFACTANT; MX 2401; OXACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CELL MEMBRANE DEPOLARIZATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ENTEROCOCCUS; FEMALE; MACROLIDE RESISTANT STREPTOCOCCUS PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS EPIDERMIDIS; METHICILLIN SENSITIVE STAPHYLOCOCCUS EPIDERMIDIS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PENICILLIN INTERMEDIATE STREPTOCOCCUS PNEUMONIAE; PENICILLIN RESISTANT STREPTOCOCCUS PNEUMONIAE; PENICILLIN SENSITIVE STREPTOCOCCUS PNEUMONIAE; PRIORITY JOURNAL; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN SENSITIVE ENTEROCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; CALCIUM; CIRCULAR DICHROISM; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS; FEMALE; LIPOPEPTIDES; MICE; MICROBIAL SENSITIVITY TESTS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PNEUMONIA, BACTERIAL; PULMONARY SURFACTANT-ASSOCIATED PROTEINS; STAPHYLOCOCCUS; STREPTOCOCCUS;

EID: 79960324969     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00322-11     Document Type: Article

References (32)

1. Angeletti, R. H., G. Ali, N. Shen, P. Gee, and E. Nieves. 1992. Effects of calcium on recombinant bovine chromogranin A. Protein Sci. 1:1604-1612. (Pubitemid 23047476)
2. Ball, L. J., C. M. Goult, J. A. Donarski, J. Micklefield, and V. Ramesh. 2004. NMR structure determination and calcium binding effects of lipopeptide antibiotic daptomycin. Org. Biomol. Chem. 2:1872-1878.
3. Banerjee, D. K. 1989. Amphomycin inhibits mannosylphosphoryldolichol synthesis by forming a complex with dolichylmonophosphate. J. Biol. Chem. 264:2024-2028.
4. Cheng, J. T. J., J. D. Hale, M. Elliott, R. E. Hancock, and S. K. Straus. 2011. The importance of bacterial membrane composition in the structure and function of aurein 2.2 and selected variants. Biochim. Biophys. Acta 1803:622-633.
5. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Document M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; 18th informational supplement. Approved standard MS100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Cooper, M. A., Y. F. Jin, J. P. Ashby, J. M. Andrews, and R. Wise. 1990. In-vitro comparison of the post-antibiotic effect of vancomycin and teicoplanin. J. Antimicrob. Chemother. 26:203-207.
8. Craig, W., and S. Gudmundsson. 1996. Postantibiotic effect, p. 296-329. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. Williams & Wilkins, Baltimore, MD.
9. Craig, W. A., D. Andes, and T. Satmstad. 2010. In vivo pharmacodynamics of a new lipopeptide MX-2401. Antimicrob. Agents Chemother. 54:5092-5098.
10. Dugourd, D., et al. 2005. Novel lipopeptide amphomycin derivatives have activity against resistant and sensitive Gram-positive bacteria, abstr. A-086. Abstr. 105th Gen. Meet. Am. Soc. Microbiol.
11. 2+ and albumin on these drugs. Antimicrob. Agents Chemother. 35:1710-1716.
12. Ho, S. W., et al. 2008. Effect of divalent cations on the structure of the antibiotic daptomycin. Eur. Biophys. J. 37:421-433.
13. Hoban, D. J., B. Weshnoweski, R. Vashisht, G. G. Zhanel, and D. Dugourd. 2008. In vitro activity of MX-2401, a novel lipopeptide against multi-drug resistant (MDR) Staphylococcus aureus (SA), abstr. F1-363. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother.
14. Hunter, T. H. 1950. Speculations on the mechanism of cure of bacterial endocarditis. JAMA 144:524-527.
15. Jung, D., A. Rozek, M. Okon, and R. E. W. Hancock. 2004. Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem. Biol. 11:949-957.
16. Jung, D., J. P. Powers, S. K. Straus, and R. E. W. Hancock. 2008. Lipid-specific binding of the calcium-dependent antibiotic daptomycin leads to changes in lipid polymorphism of model membranes. Chem. Phys. Lipids 154:120-128.
17. Klevens, R. M., et al. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771. (Pubitemid 47598444)
18. Lakey, J. H., R. Maget-Dana, and M. Ptak. 1988. Conformational change on calcium binding by the lipopeptide antibiotic amphomycin. A C.D. and monolayer study. Biochem. Biophys. Res. Commun. 150:384-390.
19. Muraih, J. K., A. Pearson, J. Silverman, and M. Palmer. 2011. Oligomerization of daptomycin on membranes. Biochim. Biophys. Acta 1808:1154-1160.
20. Omoni, A. O., and R. E. Aluko. 2006. Effect of cationic flaxseed protein hydrolysate fractions on the in vitro structure and activity of calmodulin-dependent endothelial nitric oxide synthase. Mol. Nutr. Food Res. 50:958-966.
21. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 2003. Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates. Antimicrob. Agents Chemother. 47:3012-3014.
22. Pasetka, C. J., D. J. Erfle, D. R. Cameron, J. J. Clement, and E. Rubinchik. 2010. Novel antimicrobial lipopeptides with long in vivo half-lives. Int. J. Antimicrob. Agents 35:182-185.
23. Reder-Christ, K., et al. 2011. Model membrane approaches to determine the role of calcium for the antimicrobial activity of friulimicin. Int. J. Antimicrob. Agents 37:256-260.
24. Rotondi, K. S., and L. M. Gierasch. 2005. A well-defined amphipathic conformation for the calcium-free cyclic lipopeptide antibiotic, daptomycin, in aqueous solution. Biopolymers 80:374-385.
25. Rubinchik, E., et al. 2011. Mechanism of action and limited cross resistance of a new lipopeptide MX-2401. Antimicrob. Agents Chemother. 55:2743-2754.
26. Safdar, N., D. Andes, and W. A. Craig. 2004. In vivo pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother. 48:63-68.
27. Sculier, J. P., and J. Klastersky. 1984. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am. J. Med. 76:429-435.
28. Silverman, J. A., N. G. Perlmutter, and H. M. Shapiro. 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:2538-2544.
29. Silverman, J. A., L. I. Mortin, A. D. G. VanPraagh, T. Li, and J. Alder. 2005. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J. Infect. Dis. 191:2149-2152.
30. Vogelman, B., S. Gudmundsson, J. Turnidge, J. Leggett, and W. A. J. Craig. 1988. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J. Infect. Dis. 157:287-298.
31. Weinstein, M. P., C. W. Stratton, H. B. Hawley, A. Ackley, and L. B. Reller. 1987. Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. Am. J. Med. 83:218-222.
32. Wunderink, R. G., J. Rello, S. K. Cammarata, R. V. Croos-Dabrera, and M. H. Kollef. 2003. Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789-1797.